268 related articles for article (PubMed ID: 30352134)
1. Variable population prevalence estimates of germline TP53 variants: A gnomAD-based analysis.
de Andrade KC; Frone MN; Wegman-Ostrosky T; Khincha PP; Kim J; Amadou A; Santiago KM; Fortes FP; Lemonnier N; Mirabello L; Stewart DR; Hainaut P; Kowalski LP; Savage SA; Achatz MI
Hum Mutat; 2019 Jan; 40(1):97-105. PubMed ID: 30352134
[TBL] [Abstract][Full Text] [Related]
2. Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history.
de Andrade KC; Mirabello L; Stewart DR; Karlins E; Koster R; Wang M; Gapstur SM; Gaudet MM; Freedman ND; Landi MT; Lemonnier N; Hainaut P; Savage SA; Achatz MI
Hum Mutat; 2017 Dec; 38(12):1723-1730. PubMed ID: 28861920
[TBL] [Abstract][Full Text] [Related]
3. Genome-first approach of the prevalence and cancer phenotypes of pathogenic or likely pathogenic germline TP53 variants.
de Andrade KC; Strande NT; Kim J; Haley JS; Hatton JN; Frone MN; Khincha PP; Thone GM; Mirshahi UL; Schneider C; Desai H; Dove JT; Smelser DT; ; ; Levine AJ; Maxwell KN; Stewart DR; Carey DJ; Savage SA
HGG Adv; 2024 Jan; 5(1):100242. PubMed ID: 37777824
[TBL] [Abstract][Full Text] [Related]
4. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
Fortuno C; James PA; Spurdle AB
Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
[TBL] [Abstract][Full Text] [Related]
6.
Terradas M; Mur P; Belhadj S; Woodward ER; Burghel GJ; Munoz-Torres PM; Quintana I; Navarro M; Brunet J; Lazaro C; Pineda M; Moreno V; Capella G; Evans DGR; Valle L
Gut; 2021 Jun; 70(6):1139-1146. PubMed ID: 32998877
[TBL] [Abstract][Full Text] [Related]
7. Clinical and molecular characterization of patients fulfilling Chompret criteria for Li-Fraumeni syndrome in Southern Brazil.
Matzenbacher Bittar C; de Araújo Rocha YM; Vieira IA; Rosset C; Andreis TF; Sartor ITS; Artigalás O; Netto CBO; Alemar B; Macedo GS; Ashton-Prolla P
PLoS One; 2021; 16(9):e0251639. PubMed ID: 34529667
[TBL] [Abstract][Full Text] [Related]
8. Evolution of germline TP53 variant classification in children with cancer.
Tallis E; Scollon S; Ritter DI; Plon SE
Cancer Genet; 2022 Jun; 264-265():29-32. PubMed ID: 35306447
[TBL] [Abstract][Full Text] [Related]
9. Inherited TP53 Variants and Risk of Prostate Cancer.
Maxwell KN; Cheng HH; Powers J; Gulati R; Ledet EM; Morrison C; Le A; Hausler R; Stopfer J; Hyman S; Kohlmann W; Naumer A; Vagher J; Greenberg SE; Naylor L; Laurino M; Konnick EQ; Shirts BH; AlDubayan SH; Van Allen EM; Nguyen B; Vijai J; Abida W; Carlo MI; Dubard-Gault M; Lee DJ; Maese LD; Mandelker D; Montgomery B; Morris MJ; Nicolosi P; Nussbaum RL; Schwartz LE; Stadler Z; Garber JE; Offit K; Schiffman JD; Nelson PS; Sartor O; Walsh MF; Pritchard CC
Eur Urol; 2022 Mar; 81(3):243-250. PubMed ID: 34863587
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
[TBL] [Abstract][Full Text] [Related]
11. Functional characterization of novel germline TP53 variants in Swedish families.
Kharaziha P; Ceder S; Axell O; Krall M; Fotouhi O; Böhm S; Lain S; Borg Å; Larsson C; Wiman KG; Tham E; Bajalica-Lagercrantz S
Clin Genet; 2019 Sep; 96(3):216-225. PubMed ID: 31081129
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.
Gallardo-Alvarado LN; Tusié-Luna MT; Tussié-Luna MI; Díaz-Chávez J; Segura YX; Bargallo-Rocha E; Villarreal C; Herrera-Montalvo LA; Herrera-Medina EM; Cantu-de Leon DF
BMC Cancer; 2019 Feb; 19(1):118. PubMed ID: 30709381
[TBL] [Abstract][Full Text] [Related]
13. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
[TBL] [Abstract][Full Text] [Related]
14. Challenging interpretation of germline TP53 variants based on the experience of a national comprehensive cancer centre.
Butz H; Bozsik A; Grolmusz V; Szőcs E; Papp J; Patócs A
Sci Rep; 2023 Aug; 13(1):14259. PubMed ID: 37653074
[TBL] [Abstract][Full Text] [Related]
15. p53 major hotspot variants are associated with poorer prognostic features in hereditary cancer patients.
Fortuno C; Pesaran T; Dolinsky J; Yussuf A; McGoldrick K; Kho PF; James PA; Spurdle AB
Cancer Genet; 2019 Jun; 235-236():21-27. PubMed ID: 31296311
[TBL] [Abstract][Full Text] [Related]
16. Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome.
Amadou A; Achatz MIW; Hainaut P
Curr Opin Oncol; 2018 Jan; 30(1):23-29. PubMed ID: 29076966
[TBL] [Abstract][Full Text] [Related]
17. A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically.
Coffee B; Cox HC; Bernhisel R; Manley S; Bowles K; Roa BB; Mancini-DiNardo D
Hum Mutat; 2020 Jan; 41(1):203-211. PubMed ID: 31490007
[TBL] [Abstract][Full Text] [Related]
18. Next generation sequencing is informing phenotype: a TP53 example.
O'Shea R; Clarke R; Berkley E; Giffney C; Farrell M; O'Donovan E; Gallagher DJ
Fam Cancer; 2018 Jan; 17(1):123-128. PubMed ID: 28509937
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of cancer-associated TP53 variants in the gnomAD database: A word of caution concerning the use of variant filtering.
Soussi T; Leroy B; Devir M; Rosenberg S
Hum Mutat; 2019 May; 40(5):516-524. PubMed ID: 30720243
[TBL] [Abstract][Full Text] [Related]
20. The first two confirmed sub-Saharan African families with germline TP53 mutations causing Li-Fraumeni syndrome.
Macaulay S; Goodyear QC; Kruger M; Chen W; Essop F; Krause A
Fam Cancer; 2018 Oct; 17(4):607-613. PubMed ID: 29392648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
